Form 4: J&J Executive Reports Significant Stock Transactions

Jennifer L. Taubert, EVP at Johnson & Johnson, reported multiple transactions involving common stock, restricted share units, performance share units, and stock options.

Summary

• Jennifer L. Taubert, EVP, WWC. Innovative Medicine, reported transactions under Johnson & Johnson's Long-Term Incentive Plan.
• On February 13, 2026, 1,302 shares of Common Stock were acquired upon the vesting of Restricted Share Units (RSUs) granted on February 13, 2023.
• On February 13, 2026, 409 shares of Common Stock were disposed of at $244.55 for tax withholding related to RSU vesting.
• On February 13, 2026, 27,412 shares of Common Stock were acquired upon the vesting of Performance Share Units (PSUs) granted on February 13, 2023.
• On February 13, 2026, 13,547 shares of Common Stock were disposed of at $244.55 for tax withholding related to PSU vesting.
• On February 15, 2026, 1,594 shares of Common Stock were acquired upon the vesting of RSUs granted on February 15, 2024.
• On February 15, 2026, 816 shares of Common Stock were disposed of at $243.45 for tax withholding related to RSU vesting.
• On February 15, 2026, 1,847 shares of Common Stock were acquired upon the vesting of RSUs granted on February 15, 2025.
• On February 15, 2026, 945 shares of Common Stock were disposed of at $243.45 for tax withholding related to RSU vesting.
• On February 15, 2026, 54,869 Employee Stock Options were awarded with an exercise price of $243.45, vesting in three equal annual installments starting one year from the grant date.
• On February 15, 2026, 3,940 Restricted Share Units were awarded, vesting in three annual equal installments starting one year from the grant date.
• Following these transactions, Jennifer L. Taubert beneficially owns 194,451.001 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation activities, reflecting the ongoing operation of Johnson & Johnson's long-term incentive plans and a commitment to executive retention and performance alignment.

Positives

• The executive received a significant number of shares (32,155) from the vesting of previously granted Restricted Share Units and Performance Share Units.
• New long-term incentive awards were granted, including 54,869 Employee Stock Options and 3,940 Restricted Share Units, aligning executive interests with long-term company performance.

Future Outlook

The newly granted Restricted Share Units and Employee Stock Options are scheduled to vest in three equal annual installments, beginning on the first anniversary of their respective grant dates (February 15, 2026).

Industry Context

StockSavvy.ai notes that equity compensation, including Restricted Share Units, Performance Share Units, and Stock Options, is a standard and widely adopted practice across large-cap pharmaceutical and consumer health companies like Johnson & Johnson. These awards are crucial for attracting, retaining, and incentivizing senior executives by aligning their financial interests with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of RSUs, PSUs, and stock options with multi-year vesting schedules, is consistent with industry benchmarks for executive compensation in the pharmaceutical and healthcare sectors.
• Comparable companies such as Pfizer (PFE) and Merck & Co. (MRK) typically utilize similar long-term incentive plans to reward and retain their top executives, often involving grants of performance-based and time-based equity awards.

Related Party Transactions

• Transactions involving the vesting and exercise of equity awards and subsequent share disposals for tax purposes between Johnson & Johnson and its EVP, Jennifer L. Taubert, as part of the Issuer's Long-Term Incentive Plan.

Stakeholder Impact

• Shareholders: The vesting and granting of equity awards can lead to minor share dilution over time, but also serves to align executive incentives with long-term shareholder value creation.
• Employees: Reflects the company's established compensation framework for senior leadership, potentially influencing broader employee incentive programs.

Next Steps

• Future vesting of 1,594 Restricted Share Units (granted Feb 15, 2024) in two subsequent annual installments.
• Future vesting of 1,847 Restricted Share Units (granted Feb 15, 2025) in two subsequent annual installments.
• Future vesting of 54,869 Employee Stock Options (granted Feb 15, 2026) in three equal annual installments.
• Future vesting of 3,940 Restricted Share Units (granted Feb 15, 2026) in three equal annual installments.

Key Dates

Recommendation

This Form 4 details routine executive compensation transactions, including the vesting of previously granted equity awards and the grant of new stock options and restricted share units. These are standard practices for executive incentive and retention and do not provide new fundamental information to alter an investment thesis for Johnson & Johnson. Therefore, a 'hold' recommendation is appropriate as this filing does not present new catalysts for significant price movement.

Keywords

Johnson & Johnson, JNJ, Form 4, Insider Transaction, Executive Compensation, Restricted Share Units, Performance Share Units, Stock Options, Equity Awards